Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Ингибиторы SGLT2 и острая декомпенсация сердечной недостаточности, что мы знаем?
Лаптева А.Е., Насонова С.Н., Жиров И.В., Терещенко С.Н. Ингибиторы SGLT2 и острая декомпенсация сердечной недостаточности, что мы знаем? Терапевтический архив. 2022;94(4):565–571.
DOI: 10.26442/00403660.2022.04.201449
DOI: 10.26442/00403660.2022.04.201449
________________________________________________
Lapteva AE, Nasonova SN, Zhirov IV, Tereshchenko SN. SGLT2 inhibitors in acute decompensated heart failure, what do we know? Terapevticheskii Arkhiv (Ter. Arkh.). 2022;94(4):565–571.
DOI: 10.26442/00403660.2022.04.201449
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
В настоящее время распространенность хронической сердечной недостаточности во всем мире постоянно увеличивается, а сочетание данного синдрома с другими заболеваниями кардиологического и некардиологического профиля определяет неблагоприятный прогноз у данных пациентов. В свою очередь, острая декомпенсация хронической сердечной недостаточности сопряжена с низкой выживае-
мостью больных во многом за счет поражения органов-мишеней. Изучение влияния раннего назначения ингибиторов натрий-глюкозного котранспортера 2-го типа (SGLT-2) на функцию почек у пациентов с острой декомпенсацией сердечной недостаточности, возможно, позволит улучшить результаты лечения и будет способствовать частичному или полному восстановлению почечной функции. Целью обзора являлись сбор и анализ имеющихся на сегодняшний день данных по применению ингибиторов SGLT2 у пациентов с острой декомпенсацией хронической сердечной недостаточности. Проведены систематический поиск и анализ результатов исследований, опубликованных с 2018 по 2021 г. в базах данных Web of Science, Scopus, PubMed/MEDLINE.
Ключевые слова: хроническая сердечная недостаточность, острая декомпенсация хронической сердечной недостаточности, сахарный диабет 2-го типа, ингибиторы SGLT-2, сердечно-сосудистые исходы
мостью больных во многом за счет поражения органов-мишеней. Изучение влияния раннего назначения ингибиторов натрий-глюкозного котранспортера 2-го типа (SGLT-2) на функцию почек у пациентов с острой декомпенсацией сердечной недостаточности, возможно, позволит улучшить результаты лечения и будет способствовать частичному или полному восстановлению почечной функции. Целью обзора являлись сбор и анализ имеющихся на сегодняшний день данных по применению ингибиторов SGLT2 у пациентов с острой декомпенсацией хронической сердечной недостаточности. Проведены систематический поиск и анализ результатов исследований, опубликованных с 2018 по 2021 г. в базах данных Web of Science, Scopus, PubMed/MEDLINE.
Ключевые слова: хроническая сердечная недостаточность, острая декомпенсация хронической сердечной недостаточности, сахарный диабет 2-го типа, ингибиторы SGLT-2, сердечно-сосудистые исходы
________________________________________________
The current worldwide prevalence of heart failure is growing, while its combination with cardiovascular and other conditions determines a poor prognosis in these patients. Furthermore, acute decompensated heart failure is associated with a low survival rate mostly caused by target organ damage. The effects of early administration of SGLT2 inhibitors on renal function in patients with acute decompensated heart failure are being studied to determine the possibility of improving response to treatment, as well as partial or complete recovery of renal function. The goal of the review was to synthesize currently available evidence for the use of SGLT2 inhibitors in patients with acute decompensated heart failure. A systematic search for studies published from 2018 to 2021 and their analysis was carried out in the following databases: Web of Science, Scopus, PubMed/MEDLINE.
Keywords: chronic heart failure, acute decompensated heart failure, type 2 diabetes mellitus, SGLT2 inhibitors, cardiovascular outcomes
Полный текст
Список литературы
1. Savarese G, Lund LH. Global Public Health Burden of Heart Failure. Card Fail Rev. 2017;3(1):7-11. DOI:10.15420/cfr.2016:25:2
2. Поляков Д.С., Фомин И.В., Беленков Ю.Н., и др. Хроническая сердечная недостаточность в Российской Федерации: что изменилось за 20 лет наблюдения? Результаты исследования ЭПОХА-ХСН. Кардиология. 2021;61(4):4-14 [Polyakov DS, Fomin IV, Belenkov YuN, et al. Chronic heart failure in the Russian Federation: what has changed over 20 years of follow-up? Results of the EPOCH-CHF study. Kardiologiia. 2021;61(4):4-14 (in Russian)]. DOI:10.18087/cardio.2021.4.n1628
3. Chioncel O, Mebazaa A, Maggioni AP, et al. Acute heart failure congestion and perfusion status – impact of the clinical classification on in-hospital and long-term outcomes; insights from the ESC-EORP-HFA Heart Failure Long-Term Registry. Eur J Heart Fail. 2019;21(11):1338‑52. DOI:10.1002/ejhf.1492
4. Echouffo-Tcheugui JB, Xu H, DeVore AD, et al. Temporal trends and factors associated with diabetes mellitus among patients hospitalized with heart failure: Findings from Get With The Guidelines-Heart Failure registry. Am Heart J. 2016;182:9-20. DOI:10.1016/j.ahj.2016.07.025
5. Fonarow GC. Diabetes medications and heart failure: recognizing the risk. Circulation. 2014;130(18):1565-7. DOI:10.1161/CIRCULATIONAHA.114.012883
6. McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599-726. DOI:10.1093/eurheartj/ehab368
7. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117‑28. DOI:10.1056/NEJMoa1504720
8. Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377:644-57. DOI:10.1056/NEJMoa1611925
9. Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl J Med. 2019;380(24):2295‑306. DOI:10.1056/NEJMoa1811744
10. Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380:347-57. DOI:10.1056/NEJMoa1812389
11. Cannon CP, McGuire DK, Pratley R, et al. Design and baseline characteristics of the eValuation of ERTugliflozin effIcacy and Safety CardioVascular outcomes trial (VERTIS-CV). Am Heart J. 2018;206:11-23. DOI:10.1016/j.ahj.2018.08.016
12. Cosentino F, Cannon CP, Cherney DZI, et al. Efficacy of Ertugliflozin on Heart Failure-Related Events in Patients With Type 2 Diabetes Mellitus and Established Atherosclerotic Cardiovascular Disease: Results of the VERTIS CV Trial. Circulation. 2020;142(23):2205-15. DOI:10.1161/CIRCULATIONAHA.120.050255
13. Arnott C, Li Q, Kang A, et al. Sodium-Glucose Cotransporter 2 Inhibition for the Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis. J Am Heart Assoc. 2020;9(3):e014908. DOI:10.1161/JAHA.119.014908
14. McMurray JJ, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995-2008. DOI:10.1056/NEJMoa1911303
15. Nassif ME, Windsor S, Tang F, et al. Dapagliflozin effects on biomarkers, symptoms, and functional status in patients with heart failure with reduced ejection fraction: the
DEFINE-HF trial. Circulation. 2019;140(18):1463-76. DOI:10.1161/CIRCULATIONAHA.119.042929
16. Packer M, Butler J, Filippatos GS, et al. Evaluation of the effect of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR-Reduced trial. Eur J Heart Fail. 2019;21:1270-8. DOI:10.1002/ejhf.1536
17. Packer M, Anker SD, Butler J, et al. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. N Engl J Med. 2020;383(15):1413‑24. DOI:10.1056/NEJMoa2022190
18. Anker SD, Butler J, Filippatos G, at al. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. N Engl J Med. 2021;385(16):1451-61. DOI:10.1056/NEJMoa2107038
19. McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599-726. DOI:10.1093/eurheartj/ehab368
20. Damman K, Beusekamp JC, Boorsma EM, et al. Randomized, double-blind, placebo-controlled, multicentre pilot study on the effects of empagliflozin on clinical outcomes in patients with acute decompensated heart failure (EMPA-RESPONSE-AHF). Eur J Heart Fail. 2020;22(4):713-22. DOI:10.1002/ejhf.1713
21. Boorsma EM, Beusekamp JC, Ter Maaten JM, et al. Effects of empagliflozin on renal sodium and glucose handling in patients with acute heart failure. Eur J Heart Fail. 2021;23(1):68-78. DOI:10.1002/ejhf.2066
22. Beusekamp JC, Tromp J, Boorsma EM, et al. Effects of sodium-glucose co-transporter 2 inhibition with empagliflozin on potassium handling in patients with acute heart failure. Eur J Heart Fail. 2021;23(6):1049-52. DOI:10.1002/ejhf.2197
23. Tromp J, Ponikowski P, Salsali A, et al. Sodium-glucose co-transporter 2 inhibition in patients hospitalized for acute decompensated heart failure: rationale for and design of the EMPULSE trial. Eur J Heart Fail. 2021;23(5):826-34. DOI:10.1002/ejhf.2137
24. Bavry AA, Bhatt DL. Empagliflozin in Patients Hospitalized for Acute Heart Failure – EMPULSE. November 14, 2021. Available at: https://www.acc.org/Latest-in-Cardiology/Clinical-Trials/2021/11/12/00/29/EMPULSE. Accessed: 06.12.2021.
25. Szarek M, Bhatt DL, Steg PG, et al. Effect of Sotagliflozin on Total Hospitalizations in Patients With Type 2 Diabetes and Worsening Heart Failure: A Randomized Trial. Ann Intern Med. 2021;174(8):1065-72. DOI:10.7326/M21-0651
26. Tamaki S, Yamada T, Watanabe T, et al. Effect of Empagliflozin as an Add-On Therapy on Decongestion and Renal Function in Patients With Diabetes Hospitalized for Acute Decompensated Heart Failure: A Prospective Randomized Controlled Study. Circ Heart Fail. 2021;14(3):e007048. DOI:10.1161/CIRCHEARTFAILURE.120.007048
27. Nakagaito M, Joho S, Ushijima R, et al. Comparison of Canagliflozin, Dapagliflozin and Empagliflozin Added to Heart Failure Treatment in Decompensated Heart Failure Patients With Type 2 Diabetes Mellitus. Circ Rep. 2019;1(10):405-13. DOI:10.1253/circrep.CR-19-0070
28. Nakagaito M, Imamura T, Joho S, et al. Efficacy of Continuing SGLT2 Inhibitors on Outcomes in Patients with Acute Decompensated Heart Failure. Int Heart J. 2021;62(4):885-90. DOI:10.1536/ihj.21-022
29. Effects of Empagliflozin on Diuresis and Renal Function in Patients With Acute Decompensated Heart Failure (EMPAG-HF). ClinicalTrials.gov. August 7, 2019. Available at: https://clinicaltrials.gov/ct2/show/NCT04049045. Accessed: 06.12.2021.
30. Cox ZL, Collins SP, Aaron M, et al. Efficacy and safety of dapagliflozin in acute heart failure: Rationale and design of the DICTATE-AHF trial. Am Heart J. 2021;232:116-24. DOI:10.1016/j.ahj.2020.10.071
31. Dapagliflozin and Effect on Cardiovascular Events in Acute Heart Failure – Thrombolysis in Myocardial Infarction 68 (DAPA ACT HF-TIMI 68). ClinicalTrials.gov. April 27, 2020. Available at: https://clinicaltrials.gov/ct2/show/NCT04363697. Accessed: 06.12.2021.
2. Поляков Д.С., Фомин И.В., Беленков Ю.Н., и др. Хроническая сердечная недостаточность в Российской Федерации: что изменилось за 20 лет наблюдения? Результаты исследования ЭПОХА-ХСН. Кардиология. 2021;61(4):4-14 [Polyakov DS, Fomin IV, Belenkov YuN, et al. Chronic heart failure in the Russian Federation: what has changed over 20 years of follow-up? Results of the EPOCH-CHF study. Kardiologiia. 2021;61(4):4-14 (in Russian)]. DOI:10.18087/cardio.2021.4.n1628
3. Chioncel O, Mebazaa A, Maggioni AP, et al. Acute heart failure congestion and perfusion status – impact of the clinical classification on in-hospital and long-term outcomes; insights from the ESC-EORP-HFA Heart Failure Long-Term Registry. Eur J Heart Fail. 2019;21(11):1338‑52. DOI:10.1002/ejhf.1492
4. Echouffo-Tcheugui JB, Xu H, DeVore AD, et al. Temporal trends and factors associated with diabetes mellitus among patients hospitalized with heart failure: Findings from Get With The Guidelines-Heart Failure registry. Am Heart J. 2016;182:9-20. DOI:10.1016/j.ahj.2016.07.025
5. Fonarow GC. Diabetes medications and heart failure: recognizing the risk. Circulation. 2014;130(18):1565-7. DOI:10.1161/CIRCULATIONAHA.114.012883
6. McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599-726. DOI:10.1093/eurheartj/ehab368
7. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117‑28. DOI:10.1056/NEJMoa1504720
8. Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377:644-57. DOI:10.1056/NEJMoa1611925
9. Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl J Med. 2019;380(24):2295‑306. DOI:10.1056/NEJMoa1811744
10. Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380:347-57. DOI:10.1056/NEJMoa1812389
11. Cannon CP, McGuire DK, Pratley R, et al. Design and baseline characteristics of the eValuation of ERTugliflozin effIcacy and Safety CardioVascular outcomes trial (VERTIS-CV). Am Heart J. 2018;206:11-23. DOI:10.1016/j.ahj.2018.08.016
12. Cosentino F, Cannon CP, Cherney DZI, et al. Efficacy of Ertugliflozin on Heart Failure-Related Events in Patients With Type 2 Diabetes Mellitus and Established Atherosclerotic Cardiovascular Disease: Results of the VERTIS CV Trial. Circulation. 2020;142(23):2205-15. DOI:10.1161/CIRCULATIONAHA.120.050255
13. Arnott C, Li Q, Kang A, et al. Sodium-Glucose Cotransporter 2 Inhibition for the Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis. J Am Heart Assoc. 2020;9(3):e014908. DOI:10.1161/JAHA.119.014908
14. McMurray JJ, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995-2008. DOI:10.1056/NEJMoa1911303
15. Nassif ME, Windsor S, Tang F, et al. Dapagliflozin effects on biomarkers, symptoms, and functional status in patients with heart failure with reduced ejection fraction: the
DEFINE-HF trial. Circulation. 2019;140(18):1463-76. DOI:10.1161/CIRCULATIONAHA.119.042929
16. Packer M, Butler J, Filippatos GS, et al. Evaluation of the effect of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR-Reduced trial. Eur J Heart Fail. 2019;21:1270-8. DOI:10.1002/ejhf.1536
17. Packer M, Anker SD, Butler J, et al. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. N Engl J Med. 2020;383(15):1413‑24. DOI:10.1056/NEJMoa2022190
18. Anker SD, Butler J, Filippatos G, at al. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. N Engl J Med. 2021;385(16):1451-61. DOI:10.1056/NEJMoa2107038
19. McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599-726. DOI:10.1093/eurheartj/ehab368
20. Damman K, Beusekamp JC, Boorsma EM, et al. Randomized, double-blind, placebo-controlled, multicentre pilot study on the effects of empagliflozin on clinical outcomes in patients with acute decompensated heart failure (EMPA-RESPONSE-AHF). Eur J Heart Fail. 2020;22(4):713-22. DOI:10.1002/ejhf.1713
21. Boorsma EM, Beusekamp JC, Ter Maaten JM, et al. Effects of empagliflozin on renal sodium and glucose handling in patients with acute heart failure. Eur J Heart Fail. 2021;23(1):68-78. DOI:10.1002/ejhf.2066
22. Beusekamp JC, Tromp J, Boorsma EM, et al. Effects of sodium-glucose co-transporter 2 inhibition with empagliflozin on potassium handling in patients with acute heart failure. Eur J Heart Fail. 2021;23(6):1049-52. DOI:10.1002/ejhf.2197
23. Tromp J, Ponikowski P, Salsali A, et al. Sodium-glucose co-transporter 2 inhibition in patients hospitalized for acute decompensated heart failure: rationale for and design of the EMPULSE trial. Eur J Heart Fail. 2021;23(5):826-34. DOI:10.1002/ejhf.2137
24. Bavry AA, Bhatt DL. Empagliflozin in Patients Hospitalized for Acute Heart Failure – EMPULSE. November 14, 2021. Available at: https://www.acc.org/Latest-in-Cardiology/Clinical-Trials/2021/11/12/00/29/EMPULSE. Accessed: 06.12.2021.
25. Szarek M, Bhatt DL, Steg PG, et al. Effect of Sotagliflozin on Total Hospitalizations in Patients With Type 2 Diabetes and Worsening Heart Failure: A Randomized Trial. Ann Intern Med. 2021;174(8):1065-72. DOI:10.7326/M21-0651
26. Tamaki S, Yamada T, Watanabe T, et al. Effect of Empagliflozin as an Add-On Therapy on Decongestion and Renal Function in Patients With Diabetes Hospitalized for Acute Decompensated Heart Failure: A Prospective Randomized Controlled Study. Circ Heart Fail. 2021;14(3):e007048. DOI:10.1161/CIRCHEARTFAILURE.120.007048
27. Nakagaito M, Joho S, Ushijima R, et al. Comparison of Canagliflozin, Dapagliflozin and Empagliflozin Added to Heart Failure Treatment in Decompensated Heart Failure Patients With Type 2 Diabetes Mellitus. Circ Rep. 2019;1(10):405-13. DOI:10.1253/circrep.CR-19-0070
28. Nakagaito M, Imamura T, Joho S, et al. Efficacy of Continuing SGLT2 Inhibitors on Outcomes in Patients with Acute Decompensated Heart Failure. Int Heart J. 2021;62(4):885-90. DOI:10.1536/ihj.21-022
29. Effects of Empagliflozin on Diuresis and Renal Function in Patients With Acute Decompensated Heart Failure (EMPAG-HF). ClinicalTrials.gov. August 7, 2019. Available at: https://clinicaltrials.gov/ct2/show/NCT04049045. Accessed: 06.12.2021.
30. Cox ZL, Collins SP, Aaron M, et al. Efficacy and safety of dapagliflozin in acute heart failure: Rationale and design of the DICTATE-AHF trial. Am Heart J. 2021;232:116-24. DOI:10.1016/j.ahj.2020.10.071
31. Dapagliflozin and Effect on Cardiovascular Events in Acute Heart Failure – Thrombolysis in Myocardial Infarction 68 (DAPA ACT HF-TIMI 68). ClinicalTrials.gov. April 27, 2020. Available at: https://clinicaltrials.gov/ct2/show/NCT04363697. Accessed: 06.12.2021.
________________________________________________
1. Savarese G, Lund LH. Global Public Health Burden of Heart Failure. Card Fail Rev. 2017;3(1):7-11. DOI:10.15420/cfr.2016:25:2
2. Polyakov DS, Fomin IV, Belenkov YuN, et al. Chronic heart failure in the Russian Federation: what has changed over 20 years of follow-up? Results of the EPOCH-CHF study. Kardiologiia. 2021;61(4):4-14 (in Russian). DOI:10.18087/cardio.2021.4.n1628
3. Chioncel O, Mebazaa A, Maggioni AP, et al. Acute heart failure congestion and perfusion status – impact of the clinical classification on in-hospital and long-term outcomes; insights from the ESC-EORP-HFA Heart Failure Long-Term Registry. Eur J Heart Fail. 2019;21(11):1338‑52. DOI:10.1002/ejhf.1492
4. Echouffo-Tcheugui JB, Xu H, DeVore AD, et al. Temporal trends and factors associated with diabetes mellitus among patients hospitalized with heart failure: Findings from Get With The Guidelines-Heart Failure registry. Am Heart J. 2016;182:9-20. DOI:10.1016/j.ahj.2016.07.025
5. Fonarow GC. Diabetes medications and heart failure: recognizing the risk. Circulation. 2014;130(18):1565-7. DOI:10.1161/CIRCULATIONAHA.114.012883
6. McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599-726. DOI:10.1093/eurheartj/ehab368
7. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117‑28. DOI:10.1056/NEJMoa1504720
8. Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377:644-57. DOI:10.1056/NEJMoa1611925
9. Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl J Med. 2019;380(24):2295‑306. DOI:10.1056/NEJMoa1811744
10. Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380:347-57. DOI:10.1056/NEJMoa1812389
11. Cannon CP, McGuire DK, Pratley R, et al. Design and baseline characteristics of the eValuation of ERTugliflozin effIcacy and Safety CardioVascular outcomes trial (VERTIS-CV). Am Heart J. 2018;206:11-23. DOI:10.1016/j.ahj.2018.08.016
12. Cosentino F, Cannon CP, Cherney DZI, et al. Efficacy of Ertugliflozin on Heart Failure-Related Events in Patients With Type 2 Diabetes Mellitus and Established Atherosclerotic Cardiovascular Disease: Results of the VERTIS CV Trial. Circulation. 2020;142(23):2205-15. DOI:10.1161/CIRCULATIONAHA.120.050255
13. Arnott C, Li Q, Kang A, et al. Sodium-Glucose Cotransporter 2 Inhibition for the Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis. J Am Heart Assoc. 2020;9(3):e014908. DOI:10.1161/JAHA.119.014908
14. McMurray JJ, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995-2008. DOI:10.1056/NEJMoa1911303
15. Nassif ME, Windsor S, Tang F, et al. Dapagliflozin effects on biomarkers, symptoms, and functional status in patients with heart failure with reduced ejection fraction: the
DEFINE-HF trial. Circulation. 2019;140(18):1463-76. DOI:10.1161/CIRCULATIONAHA.119.042929
16. Packer M, Butler J, Filippatos GS, et al. Evaluation of the effect of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR-Reduced trial. Eur J Heart Fail. 2019;21:1270-8. DOI:10.1002/ejhf.1536
17. Packer M, Anker SD, Butler J, et al. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. N Engl J Med. 2020;383(15):1413‑24. DOI:10.1056/NEJMoa2022190
18. Anker SD, Butler J, Filippatos G, at al. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. N Engl J Med. 2021;385(16):1451-61. DOI:10.1056/NEJMoa2107038
19. McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599-726. DOI:10.1093/eurheartj/ehab368
20. Damman K, Beusekamp JC, Boorsma EM, et al. Randomized, double-blind, placebo-controlled, multicentre pilot study on the effects of empagliflozin on clinical outcomes in patients with acute decompensated heart failure (EMPA-RESPONSE-AHF). Eur J Heart Fail. 2020;22(4):713-22. DOI:10.1002/ejhf.1713
21. Boorsma EM, Beusekamp JC, Ter Maaten JM, et al. Effects of empagliflozin on renal sodium and glucose handling in patients with acute heart failure. Eur J Heart Fail. 2021;23(1):68-78. DOI:10.1002/ejhf.2066
22. Beusekamp JC, Tromp J, Boorsma EM, et al. Effects of sodium-glucose co-transporter 2 inhibition with empagliflozin on potassium handling in patients with acute heart failure. Eur J Heart Fail. 2021;23(6):1049-52. DOI:10.1002/ejhf.2197
23. Tromp J, Ponikowski P, Salsali A, et al. Sodium-glucose co-transporter 2 inhibition in patients hospitalized for acute decompensated heart failure: rationale for and design of the EMPULSE trial. Eur J Heart Fail. 2021;23(5):826-34. DOI:10.1002/ejhf.2137
24. Bavry AA, Bhatt DL. Empagliflozin in Patients Hospitalized for Acute Heart Failure – EMPULSE. November 14, 2021. Available at: https://www.acc.org/Latest-in-Cardiology/Clinical-Trials/2021/11/12/00/29/EMPULSE. Accessed: 06.12.2021.
25. Szarek M, Bhatt DL, Steg PG, et al. Effect of Sotagliflozin on Total Hospitalizations in Patients With Type 2 Diabetes and Worsening Heart Failure: A Randomized Trial. Ann Intern Med. 2021;174(8):1065-72. DOI:10.7326/M21-0651
26. Tamaki S, Yamada T, Watanabe T, et al. Effect of Empagliflozin as an Add-On Therapy on Decongestion and Renal Function in Patients With Diabetes Hospitalized for Acute Decompensated Heart Failure: A Prospective Randomized Controlled Study. Circ Heart Fail. 2021;14(3):e007048. DOI:10.1161/CIRCHEARTFAILURE.120.007048
27. Nakagaito M, Joho S, Ushijima R, et al. Comparison of Canagliflozin, Dapagliflozin and Empagliflozin Added to Heart Failure Treatment in Decompensated Heart Failure Patients With Type 2 Diabetes Mellitus. Circ Rep. 2019;1(10):405-13. DOI:10.1253/circrep.CR-19-0070
28. Nakagaito M, Imamura T, Joho S, et al. Efficacy of Continuing SGLT2 Inhibitors on Outcomes in Patients with Acute Decompensated Heart Failure. Int Heart J. 2021;62(4):885-90. DOI:10.1536/ihj.21-022
29. Effects of Empagliflozin on Diuresis and Renal Function in Patients With Acute Decompensated Heart Failure (EMPAG-HF). ClinicalTrials.gov. August 7, 2019. Available at: https://clinicaltrials.gov/ct2/show/NCT04049045. Accessed: 06.12.2021.
30. Cox ZL, Collins SP, Aaron M, et al. Efficacy and safety of dapagliflozin in acute heart failure: Rationale and design of the DICTATE-AHF trial. Am Heart J. 2021;232:116-24. DOI:10.1016/j.ahj.2020.10.071
31. Dapagliflozin and Effect on Cardiovascular Events in Acute Heart Failure – Thrombolysis in Myocardial Infarction 68 (DAPA ACT HF-TIMI 68). ClinicalTrials.gov. April 27, 2020. Available at: https://clinicaltrials.gov/ct2/show/NCT04363697. Accessed: 06.12.2021.
Авторы
А.Е. Лаптева*1, С.Н. Насонова1, И.В. Жиров1,2, С.Н. Терещенко1,2
1 ФГБУ «Национальный медицинский исследовательский центр кардиологии им. акад. Е.И. Чазова» Минздрава России, Москва, Россия;
2 ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава России, Москва, Россия
*anastasiyalapteva95@gmail.com
1 ФГБУ «Национальный медицинский исследовательский центр кардиологии им. акад. Е.И. Чазова» Минздрава России, Москва, Россия;
2 ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава России, Москва, Россия
*anastasiyalapteva95@gmail.com
________________________________________________
Anastasiya E. Lapteva*1, Svetlana N. Nasonova1, Igor V. Zhirov1,2, Sergey N. Tereshchenko1,2
1 Chazov National Medical Research Center of Cardiology, Moscow, Russia;
2 Russian Medical Academy of Continuous Professional Education, Moscow, Russia
*anastasiyalapteva95@gmail.com
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.